What is it about?
This paper reviews all the evidence of the antimycobacterial activity of phenothiazines, most importantly thioridazine. We summarize all minimum inhibitory concentration data, synergy with other antibiotics and results of macrophage infection experiments and mouse model studies of tuberculosis and nontuberculous mycobacterial disease treatment.
Featured Image
Why is it important?
Very few balanced reviews of this class of potential antibiotics exist. Most studies are published in quaint journals and thus overlooked in other reviews.
Perspectives
Phenothiazines like thioridazine appear to have multiple mechanisms of action, including efflux pump blocking. The many uncertainties regarding their activity within macrophages and their toxicity profile render currently available phenothiazines poor options for therapy. New drugs in this class need to be developed to enable their clinical use.
Jakko van Ingen
Radboud Universiteit
Read the Original
This page is a summary of: The Broad-spectrum Antimycobacterial Activities of Phenothiazines, In Vitro: Somewhere in All of this there May be Patentable Potentials, Recent Patents on Anti-Infective Drug Discovery, May 2011, Bentham Science Publishers,
DOI: 10.2174/157489111796064623.
You can read the full text:
Contributors
The following have contributed to this page
